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Abstract
Background: Illicium verum Hook. fil. Illiciaceae (Illicium v.) has been traditionally used in herbal medicine for
treating many inflammatory diseases, including skin inflammation and rheumatism. We investigated its use as a
preventive agent against inflammatory and vascular diseases in a murine model of atherosclerosis using
apolipoprotein E-knockout (ApoE−/−) mice fed on a high-fat diet (HFD).
Methods: We investigated the effect of Illicium v. on cytotoxicity, NF-κB activity, and adhesion molecule expression
in TNF-α – stimulated HASMCs (Human Aortic smooth muscle cells). ApoE−/−mice, fed a HFD and treated daily for
12 weeks by oral administration of either Illicium v. (100 or 200 mg/kg) or atorvastatin (10 mg/kg), were evaluated
for atherosclerotic lesions and inflammatory responses by performing Oil red O and iNOS staining, respectively.
Expression of inflammatory cytokines (i.e., NF-κB, TNF-α, IL-1β, COX, IκB-α, Iκκ-α/β) and adhesion molecules in the
aorta were measured by western blot analysis.
Results: In TNF-α-stimulated HASMCs, Illicium v. treatment decreased NF-κB transcriptional activity, and NF-κB
protein levels were reduced in a dose-dependent manner over a range of 10–100 μg/mL Illicium v. Also, Illicium v.
attenuated the expression of adhesion molecules that are responsible for inflammation in these cells. In animal
experiments, treatment with Illicium v. or atorvastatin counteracted the characteristic changes in body weight, blood
pressure, and lipid levels seen in HFD-fed ApoE−/− mice. In addition, Illicium v. treatment reduced aortic atherosclerotic
plaque lesions and the immunoreactivity of iNOS activation. The aortic expression of inflammatory adhesion molecules
and cytokines (TNF-α, IL-1β, NF-κB, COX, IκB-α, Iκκ-α/β), which is characteristic of HFD-fed ApoE−/− mice, was attenuated
by 12-week treatment with daily oral administration of Illicium v. or atorvastatin, and the most potent effect was seen
with the herbal tincture.
Conclusions: The beneficial effects of Illicium v. are consistent with a significant decrease in the iNOS-mediated
inflammatory response, resulting in reduction of inflammation-associated gene expression. Treatment with Illicium v.
may be the basis of a novel therapeutic strategy for hyperlipidemia-atherosclerosis.
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Background
Hyperlipidemia plays an important role in the pathogen-
esis of atherosclerosis in prehypertension [13]. Many
studies have demonstrated that systemic inflammation
and the immune system play a central role in atherogen-
esis. Strong dependence of the atherosclerotic process
on both a state of continuous low-grade inflammation
and presence of lipid abnormalities gave impetus in the
field to examine the association between hyperlipidemia
and inflammatory status [26]. Recent studies in hyperlip-
idemic mice have demonstrated that anti-inflammatory
compounds prevent development of atherosclerosis with-
out altering blood lipid profiles [2, 12, 22]. Furthermore,
anti-inflammatory drugs there are other agents that
can reduce the occurrence of atherosclerosis without
altering blood lipid profiles in this murine model, indi-
cating that anti-inflammatory compounds may be used
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as therapeutic drugs for the treatment of hyperlipidemia-
atherosclerosis [16].
Monocytes and macrophages infiltrate areas of athero-
sclerotic lesions and increase expression of adhesion mole-
cules and inflammation-related genes, such as ICAM,
VCAM, NF-κB, and iNOS, that are important for develop-
ment and progression of atherosclerosis [3, 12]. In particu-
lar, large amount of locally released NO has been linked to
generation of harmful oxidative products, such as peroxy-
nitrite, that have been implicated in iNOS-mediated devel-
opment of atherosclerosis [31]. The hypothesis that iNOS
plays a causative role in the progression of atherosclerosis
is supported by the observation that atherosclerotic lesions
are diminished in iNOS/ApoE double-knockout mice rela-
tive to ApoE−/− mice [15]. Furthermore, iNOS expression
is activated by NF-κB, which is responsive to inflammation
and oxidative stress [23]. Therefore, understanding mech-
anisms of iNOS regulation may provide new targets for
the treatment of hyperlipidemia-atherosclerosis.
Illicium verum Hook. fil. Illiciaceae (Illicium v.), is
widely used for culinary and medicinal purposes, and it
is taken as a natural remedy by many patients. The fruit
of the plant has been used in traditional medicine for
treatment of stomach aches, vomiting, rheumatic pain,
insomnia, and skin inflammation [11, 18, 27, 30], and it
has been reported to have beneficial anti-inflammatory
effects. These effects have been shown with ethanolic
Illicium v, extracts to be mediated by suppressing the ex-
pression of TNF-α- and IFN-γ-stimulated chemokine
and cytokine expression in vitro and in vivo [20, 27, 28].
Illicium v. contains ten main chemical entities (i.e., linoleic
acid, palmitic acid, trans-anethole, anisaldehyde, estragole,
limonens, (Z)-anethole, pinene, β-phellandraene, and α-
terpineol) that have various anti-inflammatory pharmaco-
logical effects [7, 14, 25, 28].
Given the known inflammatory component in athero-
sclerosis, it is perhaps surprising that Illicium v. has
not yet been tested as a potential treatment for athero-
sclerosis or hyperlipidemia in an animal model. It is
reasonable to hypothesize that Illicium v. might be effi-
cacious because of its demonstrated anti-inflammatory
action in other settings. We hypothesized that Illicium
v. would be active as an anti-inflammatory agent in
ApoE−/− mice and would inhibit atherosclerosis in these
animals when they are fed a high-fat diet (HFD), which
is an accepted mechanism-based animal model for the
disease. A number of parameters were investigated in
vivo, such as body weight, blood lipid levels, and blood
pressure, during HFD-induced atherosclerosis to evalu-
ate activity of Illicium v. Effects of the extract on ex-
pression of atherosclerosis-related adhesion molecules and
anti-inflammatory signaling in human smooth muscle




Cryopreserved HASMC were purchased from ScienCell
Research Laboratory (San Diego, CA, USA). Cells were
cultured as monolayers in smooth muscle cell medium
(ScienCell) containing essential and nonessential amino
acids, vitamins, organic and inorganic compounds, hor-
mones, growth factors, trace minerals, and 2 % (v/v)
fetal bovine serum at 37 °C in a humidified 5 % CO2 at-
mosphere. Cells from passages 2 to 6 were used in this
study.
Experimental animals and diet
Male ApoE−/− mice in a C57BL/6 N background (6 weeks
of age) were from the Jackson Laboratory (Bar Harbor,
ME, USA). They were housed under diurnal lighting
conditions and allowed food and tap water ad libitum.
All experimental protocols involving use of animals were
conducted in accordance with the National Institutes of
Health guidelines and approved by the Committee on
Animal Care of KIOM.
The mice fed on a High Fat diet (45 % of total calo-
ries from fat; 0.15 % cholesterol; Research Diet, New
Brunswick, NJ, USA) were divided into five groups:
control (chow diet, n = 8), HFD (High Fat Diet, n = 8),
Illicium v. 100 mg/kg treatment (HFD with Illicium v.
100 mg/kg, n = 8), Illicium v. 200 mg/kg (HFD with Illi-
cium v. 200 mg/kg, n = 8), and atorvastatin 10 mg/kg
(HFD with atorvastatin 10 mg/kg, n = 8). Daily treat-
ments were given orally over a 12-week period, during
which experimental animals were fed a HFD.
Preparation of Illicium verum extract
Illicium v. material was purchased from Omniherb Co.
(Yeongcheon, South Korea) and was authenticated based
on its microscopic and macroscopic characteristics by
the Classification and Identification Committee of the
KIOM. A voucher specimen has been deposited at the
herbarium of the Basic Herbal Medicine Research Group
at KIOM. Dried fruit (300 g) was extracted twice with
70 % (v/v) ethanol (with a 2-h reflux). The extract was
concentrated under reduced pressure at 40 °C with a ro-
tary evaporator. The decoction was filtered, lyophilized,
and stored at 4 °C until use (Sung et al. [27]). The yield
of the dried extract from the starting crude materials
was approximately 15.73 % (w/w). The lyophilized pow-
der was dissolved in 0.05–0.1 % dimethyl sulfoxide and
then filtered through a 0.22 μm syringe filter to create a
stock solution.
Cell viability
A standard assay based on the tetrazole (3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
was used to assess cell viability. Briefly, HASMCs were
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seeded in 96-well microtiter plates at a density of 1 × 105
cells/well. They were treated with various concentra-
tions of Illicium v. (10, 50, or 100 μg/mL) for 24 h.
Subsequently, 100 μL of 5 mg MTT/mL in PBS was
added to each well, and the plates were incubated at
37 °C for 4 h before adding 200 μL DMSO to dissolve
formazan crystals. Absorbance was measured at 540 nm
by spectrophotometry.
NF-κB activity assay
Activity of NF-κB was measured by luciferase reporter
assays in HASMC. Cells in 12-well plates were cotrans-
fected with a firefly luciferase gene tagged with renilla
luciferase and pGL4.32-NF-κB, using the FuGENE HD
reagent (Invitrogen; Carlsbad, CA, USA). Medium was
replaced with fresh medium after 6 h. At 24 h post
transfection, cells were stimulated with TNF-α (10 ng/
mL, R&D Systems Inc.; St. Louis, Mo, USA) in the pres-
ence of 10, 50, or 100 μg Illicium v../mL. Luciferase ac-
tivity was assayed 24 h later using a dual-luciferase
reporter assay system (Promega; Madison, Wl, USA).
Measurement of serum markers
Blood was collected from the aorta under light anesthesia
and stored on ice for 30 min before centrifugation at
13,000 rpm at 4 °C for 10 min, and the serum was sepa-
rated and kept at −80 °C until it was thawed for the assay.
Serum levels of total cholesterol, high-density lipoprotein
(HDL), low-density lipoprotein (LDL), triglycerides, glu-
cose, alanine aminotransferase (ALT), aspartate amino-
transferase (AST), and creatinine were measured with an
automatic analyzer.
Blood pressure measurement
Blood pressure was monitored using a noninvasive tail-
cuff CODATM system (Kent Scientific; Torrington, CT,
USA) as previously described [17].
Histopathology
Mice were deeply anesthetized with sodium thiopental
and subsequently the tissue was removed and then washed
with cold PBS and followed fixation with 4 % (w/v) para-
formaldehyde. The aorta of each mouse was then removed
and further fixed in the same solution for 24 h at 4 °C.
Fixed aortas were frozen and stored at −80 °C. Sections of
10-μm thickness were sliced from frozen tissue and then
immunostained with antibodies against iNOS(Thermo
Scientific; Rockford, IL USA). After additional incubation
with secondary antibody, sections were reacted with 3-
amino-9-ethylcarbazole chromogen (Vector Laboratories;
Burlingame, CA, USA). Reactions with 3,3′ diaminobenzi-
dine substrate (Vector Laboratories) were performed for
color development, and the stained sections were then an-
alyzed by light microscopy.
Western blot analysis
Proteins were isolated from aortic tissue according to
standard techniques [4], separated by 10 % sodium do-
decyl sulfate-polyacrylamide gel electrophoresis and then
transferred onto nitrocellulose membranes (Amersham
Biosciences; Piscataway, NJ, USA). Blots were probed
with primary antibodies directed against VCAM-1 or
NF-κB (Santa Cruz Biotechnology; San Cruz, CA, USA),
or against ICAM-1, E-selectin, TNF-α, IL-1β, COX, IκB-
α, or Iκκ-α/β, iNOS (Cell Signaling Technology; Beverly,
MA, USA). This was followed by incubation with sec-
ondary antibody conjugated to horseradish peroxidase
(Cell Signaling). Bound secondary antibody was detected
by chemiluminescence generated by peroxidase reaction,
measured with an ImageQuant LAS 4000 apparatus (GE
Healthcare Life Sciences; Buckinghamshire, UK). Mem-
branes were reprobed with an anti-β-actin antibody
(Sigma-Aldrich Chemical Co.; St. Louis, MO, USA) as
internal sample control.
Data analysis
The data are expressed as mean values ± SEM. Statistical
comparisons were performed using analysis of variance
for repeated measures, followed by Sigmastat statistical
program Version 11.2 (Systat Software, San Jose, CA,
USA). Data were analyzed statistically using two-way
ANOVA via Tukey’s post hoc comparison when compar-
ing more than two groups. A value of P <0.05 was con-
sidered to be statistically significant.
Results
Illicium v. effects on TNF-α-stimulated HASMCs
Cytotoxic effect of Illicium v. was assessed at different
concentrations (0, 10, 50, or 100 μg/mL) by MTT assay
in HASMCs. At concentrations in this range, Illicium v.
did not cause any apparent cytotoxicity (Fig. 1a). We evalu-
ated the ability of Illicium v. to decrease pro-inflammatory
NF-κB activity in TNF-α-stimulated HASMCs. The TNF-
α-stimulated NF-κB transcription activity (22.03 ± 0.25 vs.
control group) was markedly reversed by Illicium v. in a
dose-dependent manner (Fig. 1b). The activity was de-
creased by 50 and 100 μg/mL Illicium v. decreased to
10.39 ± 0.06 and 9.17 ± 0.07, respectively (P < 0.01, P < 0.05
vs. TNF-α-stimulated group). Furthermore, NF-κB protein
level was decreased by Illicium v. in TNF-α-stimulated
HASMCs (Fig. 1c). Western blot analysis revealed that
adhesion molecule (ICAM, VCAM, and E-selectin) ex-
pression was induced in the TNF-α-stimulated group.
Illicium v. significantly antagonized TNF-α-induced ICAM,
VCAM, and E-selectin expression (Fig. 1d). Transcriptional
activity of many of these inflammatory cytokines and adhe-
sion molecules is controlled by NF-κB. These results show
that Illicium v. suppresses production of inflammatory me-
diators in vitro.
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Body weight and blood pressure in treated and untreated
HFD-fed ApoE−/− mice
Body weights of ApoE−/− mice fed on a HFD for 12 week
were higher than those in normal diet-fed mice (control)
(28.2 ± 0.60 vs. 40.0 ± 2.10 g, P < 0.001). However, the
Illicium v. 100 and 200 mg/kg group mean body weights
were significantly lower than those of mice in the HFD
group (33.5 ± 1.40 and 29.3 ± 0.78 g vs. HFD group, P <
0.01 and P < 0.001, respectively). This was similar to the
effect of atorvastatin (33.2 ± 1.85 vs. HFD group, P <
0.05; see Table 1 and Fig. 2a). Next, we confirmed that
Illicium v. reduced blood pressure. During the course of
Fig. 1 Illicium v. inhibits inflammatory gene expression in TNF-α-stimulated human aortic smooth muscle cells. a Human aortic smooth muscle
cells (HASMC) were treated with or without Illicium v. (10–100 μg/mL) for 24 h. After incubation, cell viability was determined using the MTT assay.
b HASMCs were transiently transfected with pGL4.32-NF-κB, a renilla luciferase control reporter vector, and then treated with or without Illicium v.
(10–100 μg/mL), followed by incubation with 10 ng/mL TNF-α for 24 h. NF-κB transcription activity was determined using a luciferase reporter
assay. c Protein samples from HASMCs, treated with or without Illicium v. (10–100 μg/mL) and 10 ng/mL TNF-α for 24 h, examined by western
blot analysis for NF-κB protein expression. d Protein expression of adhesion molecules (ICAM, VCAM, and E-selectin). All data represent mean
values ± SEM. **P < 0.01, ***P < 0.001 versus control; #P < 0.05, ##P < 0.01, ###P < 0.001 versus HFD
Table 1 Physiological parameters
Blood pressure (mm Hg)
Body weight (g) Mean pressure Diastolic Systolic
Con 28.2 ± 0.60 86 ± 5.559 77 ± 6.19 105 ± 3.51
HFD 40.0 ± 2.10*** 111 ± 8.80* 109 ± 8.41** 135 ± 6.52**
Illicium v., 100 mg/kg 33.5 ± 1.40# 87 ± 7.13# 79 ± 8.42## 104 ± 4.91##
Illicium v., 200 mg/kg 29.3 ± 0.78### 66 ± 2.16## 59 ± 2.04## 82 ± 2.83###
Atorvastatin 33.2 ± 1.85# 93 ± 2.66# 83 ± 1.94## 115 ± 4.84#
Abbreviations: Con, control; HFD, high-fat diet
All data represent mean values ± SEM. (n = 8)
*P < 0.05, **P < 0.01 and ***P < 0.001, versus chow diet fed ApoE−/− mice (control)
#P < 0.05, ##P < 0.01 and ###P < 0.001, versus HFD-fed ApoE−/− mice (HFD)
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the experiment, blood pressure in the HFD group was
significantly higher than that in the control group (86 ±
5.59 vs. 111 ± 8.80 mmHg, P < 0.05). In contrast, the blood
pressure was significantly lower in the groups treated with
either Illicium v. at 100 mg/kg (87 ± 7.13 mmHg, P < 0.05)
or at 200 mg/kg (66 ± 2.16 mmHg, P < 0.01) or in the ator-
vastatin group (93 ± 2.66 mmHg, P < 0.05) than HFD
group. Moreover, diastolic and systolic blood pressure
levels were significantly reduced in the Illicium v. and
atorvastatin treatment groups (Table 1 and Fig. 2b).
Blood lipid levels
Illicium v.- or atorvastatin-treated HFD-fed ApoE−/−
mice showed significantly decreased total and LDL chol-
esterol levels (P < 0.05 and P < 0.01 vs. HFD group;
Table 2). Moreover, glucose levels were decreased in Illi-
cium v. 50 mg/kg and 100 mg/kg groups (245.67 ± 14.54
and 215.33 ± 10.23 vs. HFD group, P < 0.01 and P <
0.001, respectively). Potential toxicity did not differ
among mice treated with Illicium v. or atorvastatin, at
inhibitory concentrations of both agents.
Illicium v. attenuates formation of atherosclerotic plaque
lesions
We investigated whether Illicium v. exerts an anti-
atherosclerotic effect in HFD-fed ApoE−/− mice by quan-
tifying atherosclerotic plaque lesional areas. Consecutive
cross sections of aortas stained with Oil red O revealed
induction of plaque formation. The mice that were fed a
HFD for 12 weeks exhibited significantly increased aortic
Fig. 2 Illicium v. results in improved body weight and blood pressure in high-fat diet-fed ApoE−/− mice. a Body weight ratio was measured during
the 0–12 week feeding regimen. b Blood pressure (diastolic and systolic) ratio was measured at the end of the 12-week feeding regimen. All data
represent mean values ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 versus control; #P < 0.05, ##P < 0.01, ###P < 0.001 versus HFD
Table 2 Lipid parameters
Illicium verum
Con HFD 100 mg/kg 200 mg/kg Atorvastatin
T-chole (mg/dL) 502.40 ± 22.79 1112.00 ± 120.77*** 635.50 ± 106.12# 608.00 ± 49.50## 655.25 ± 60.80#
LDL (mg/dL) 79.60 ± 7.86 244.00 ± 48.45*** 134.17 ± 22.74# 108.33 ± 15.19## 98.75 ± 17.05#
HDL (mg/dL) 16.80 ± 2.04 9.83 ± 1.30** 8.50 ± 1.46 11.44 ± 1.71 12.25 ± 2.88
TG (mg/dL) 41.00 ± 6.16 34.60 ± 3.29 33.80 ± 4.77 38.71 ± 6.35 34.50 ± 7.37
Glucose (mg/dL) 262.80 ± 9.82 418.67 ± 26.47** 245.67 ± 14.54## 215.33 ± 10.23### 371.25 ± 40.82
AST (U/L) 110.20 ± 14.88 175.17 ± 28.16 196.50 ± 49.89 162.67 ± 31.01 123.50 ± 19.75
ALT (U/L) 43.40 ± 2.70 100.67 ± 27.88 60.33 ± 8.06 46.78 ± 2.43# 49.25 ± 4.50
Creatinine (mg/dL) 0.17 ± 0.01 0.18 ± 0.01 0.19 ± 0.02 0.13 ± 0.02 0.23 ± 0.02
Abbreviations: Con, control; HFD, high-fat diet; T-chole, total cholesterol; LDL, low density lipoprotein; HDL, high density lipoprotein; TG, triglyceride; AST, aspartate
aminotransferase; ALT, alanine aminotransferase
All data represent mean values ± SEM. (n = 8)
**P < 0.01, ***P < 0.001, versus chow diet fed ApoE−/− mice (control)
#P < 0.05, ##P < 0.01, and ###P < 0.001, versus HFD-fed ApoE−/− mice (HFD)
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atherogenic plaque areas as compared to mice fed con-
trol diet (3.20 ± 1.69 vs. 58.36 ± 3.92 × 104 μm2). This in-
crease was significantly antagonized by dose-dependent
supplementation with Illicium v. (23.69 ± 3.32 and 7.87 ±
2.89 × 104 μm2) or atorvastatin (10.0 ± 4.41 × 104 μm2, P <
0.01 vs. HFD group) (Fig. 3a and b).
Illicium v. attenuates iNOS expression in the aorta
To explore action mechanisms of Illicium v. effects in
hyperlipidemia with atherosclerosis, we studied aortic
iNOS expression levels in the mouse model. Many iNOS
cells were observed in the HFD-fed ApoE−/− mice. Illi-
cium v. 200 mg/kg treatment resulted in complete re-
duction of iNOS activation in HFD-fed ApoE−/− mice
(Fig. 4a and b). Furthermore, iNOS expression was de-
creased by 200 mg/kg Illicium v. in protein of aortic tis-
sue (Fig. 4c). These data suggest an iNOS-dependent
mechanism.
Illicium v. inhibits production of inflammatory mediators
in the aorta
Previously published studies on sepsis show that high
iNOS expression is associated with inflammatory media-
tors, such as TNF-α, IL-1β, NF-κB, and COX. These me-
diators also play an important role in the development
and progression of atherosclerosis. We examined the ef-
fects of Illicium v. on expression of these proteins in
aortic tissues. Levels of secreted TNF-α, IL-1β, NF-κB,
and COX proteins were significantly increased in aortic
tissues from HFD-fed ApoE−/− mice, and these increases
were antagonized by supplementation with Illicium v.
or atorvastatin (P < 0.05, <0.01, and <0.001 vs. HFD
group) (Fig. 5a and b). In addition, IκB-α/Iκκ-α/β ex-
pression was also increased in aortic tissue from HFD-
fed ApoE−/− mice, and these increases were antagonized
by Illicium v. or atorvastatin (Fig. 5c). These results
suggest that Illicium v. regulates inflammatory gene ex-
pression via mediation of reduced iNOS activation.
Illicium v. inhibits expression levels of adhesion molecules
in the aorta
To determine involvement of adhesion molecule expres-
sion, including ICAM-1, VCAM-1, and E-selectin, in the
anti-inflammatory activities of Illicium v., protein levels
were examined in western blots (Fig. 6a and b). Levels of
ICAM-1, VCAM-1, and E-selectin were higher in aortas
of untreated HFD-fed ApoE−/− mice than normal con-
trols. Treatment with Illicium v. or atorvastatin resulted
predominantly in a dose-dependent downregulation of
ICAM-1, VCAM-1, and E-selectin expression levels in
aortas of HFD-fed ApoE−/− mice. These results indicate
that Illicium v. efficiently lowers adhesion molecule pro-
tein levels in hyperlipidemia-atherosclerosis.
Discussion
We have defined mechanisms involved in the beneficial
effects of Illicium v. on atherosclerosis plaque lesions by
investigating effects of the agent on anti-inflammatory
responses in HASMCs in vitro, and in aortas of HFD-fed
ApoE−/− mice in vivo. We report that Illicium v. de-
creases characteristic changes in body weight, blood
pressure, and lipid levels in HFD-fed ApoE−/− mice. In
addition, Illicium v. strongly attenuates atherosclerotic
plaque lesions in the aortas of those mice, and it de-
creases immunoreactivity of iNOS. Furthermore, signifi-
cantly lower levels of TNF-α, IL-1β, NF-κB, COX, IκB-α,
Iκκ-α/β and adhesion molecules were seen with Illicium
v. treatment. The results clearly demonstrate beneficial
Fig. 3 Illicium v. reduces atherosclerotic lesions in high-fat diet-fed ApoE−/− mice. The ApoE−/− mice were fed high-fat diet (HFD) with or without
Illicium v. (100 or 200 mg/kg) for 12 week. a Photographs of Oil red O staining in the aorta, showing atherosclerotic lesions from each experimental
group. b Quantification of Oil red O-stained atherosclerotic lesion areas from each group. All data represent mean values ± SEM. ***P < 0.001 versus
control; ##P < 0.01 versus HFD
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effects of Illicium v. on pathogenic atherosclerotic pla-
ques and subsequent vascular impairment by vascular
inflammation.
Pathogenesis of hyperlipidemia-atherosclerosis involves
a chronic inflammatory state characterized by lipid depos-
ition, accumulation of macrophages, and vascular smooth
muscle cell proliferation in vascular walls [24, 29]. These
are all well-known events in the development of the dis-
ease. Additionally, anti-inflammatory compounds have
been found to effectively inhibit atherosclerotic plaque for-
mation in a hyperlipidemic animal model [22]. Therefore,
an iNOS imbalance is regarded as an important cause
for the development of inflammatory-related diseases.
Abnormal activation of iNOS and enhanced levels of
inflammatory proteins, such as NF-κB, TNF-α, and cer-
tain adhesion molecules, are observed in the coronary
plaques of patients [8].
Overexpression of iNOS has a causal effect on the de-
velopment of atherosclerosis. This has been previously
established by showing that atherosclerotic lesions are
attenuated when iNOS is knocked out in ApoE−/− mice,
creating the double knock-out strain. Elucidation of fac-
tors that modulate aggregation of atherosclerotic plaques
and adhesion molecule expression is crucial for inter-
vention in hyperlipidemia-atherosclerosis [1, 9]. Several
lines of evidence suggest that iNOS effects in vascular
inflammation play a major role in hyperlipidemia patho-
genesis, and they also influence various pathogenic pro-
cesses implicated in hyperlipidemia [6]. Previous studies
in hyperlipidemic murine models have demonstrated
that lack of iNOS leads to a dramatic reduction in the
size of atherosclerotic lesions. Furthermore, iNOS regu-
lates expression of inflammatory cytokines, such as IL-
1β, Iκκ-α/β, and TNF-α, in the aorta [10, 12]. Therefore,
modulating the function or levels of proteins involved
with iNOS activity in the aorta will likely affect vascular
inflammation and, ultimately, pathogenic processes in
hyperlipidemia. In our study with HFD-fed ApoE−/−
mice, Illicium v. was found to dramatically reduce the
levels of inflammatory cytokines and adhesion mole-
cules, subsequently improving atherosclerotic lesions.
Moreover, Illicium v. reduced NF-κB expression. There-
fore, the mechanism(s) of Illicium v. may reveal potential
new targets for hyperlipidemia-atherosclerosis therapy,
through its inhibitory activities against atherosclerotic le-
sion growth/aggregation and/or inflammatory responses.
Moreover, Illicium v. decreased the activation of iNOS,
which is responsible for inflammatory and atherogenic
processes, in a dose-dependent manner in both HASMCs
and in aortas of HFD-fed ApoE−/− mice. Thus, results of
Fig. 4 Representative histological cross section of the aorta in high-fat diet-fed ApoE−/− mice. The ApoE−/− mice were fed high-fat diet (HFD) with
or without Illicium v. (100 or 200 mg/kg) for 12 week. a and b Aorta tissue samples were excised, fixed in 4 % formaldehyde, embedded in paraffin and
then sectioned. Immunohistochemistry of sections stained for iNOS (A, magnification × 200; B, ×400). c Protein levels of iNOS were determined
by western blot analysis
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Fig. 6 Illicium v. suppresses adhesion molecule expression in aortas from high-fat diet-fed ApoE−/− mice. a Protein levels of ICAM-1, VCAM-1, and
E-selectin were determined by western blot analysis. b Relative abundance of protein was calculated by ratio for ICAM-1, VCAM-1, and E-selectin.
All data represent mean values ± SEM. ***P < 0.001 versus control; #P < 0.05, ##P < 0.01, ###P < 0.001 versus HFD
Fig. 5 Illicium v. decreases expression levels of NF-κB and other inflammatory genes in aortas from high-fat diet-fed ApoE−/− mice. a Expression
levels of TNF-α, IL-1β, NF-κB, and COX were determined by western blot analysis. b Relative abundance of protein was calculated by ratio for
expressed TNF-α, IL-1β, NF-κB, and COX. c Total protein expression and phosphorylation of IκB-α and Iκκ-α/β were detected by western blot
analysis. All data represent mean values ± SEM. ***P < 0.001 versus control; #P < 0.05, ##P < 0.01, ###P < 0.001 versus HFD
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the present study suggest that beneficial effects of Illicium
v. may be mediated through significant attenuation of the
iNOS inflammatory response.
We recently reported that major chemical constituent
of Illicium v. is trans-anethole [1-methoxy-4-(1-prope-
nyl) benzene], which accounts for approximately 85–
90 % of the essential oil. Previous reports had indicated
that ethanol extracts of Illicium v. contain high levels,
approximately 2.14 ± 0.01 mg/g, of trans-anethole [28],
and the anti-inflammatory and anti-oxidant effects of
that compound occur through inhibition of lipid peroxi-
dation [10]. In other studies, trans-anethole was found
to decrease production of IL-1β, IL-6, and TARC, to
have anti-inflammatory properties in HaCaT cells, and to
have anticarcinogenic properties through inhibition of
TNF-α-stimulated cellular responses [5, 30]. Hence,
trans-anethole may play a substantial role in the action
of Illicium v. that we have described in our hyperlipid-
emia model.
We observed iNOS-positive immunostaining and ele-
vated inflammatory cytokine expression, such as IL-1β,
Iκκ α/β, and TNF-α, in aortas of HFD-fed ApoE−/− mice
compared to controls, and these effects were practically
abolished by Illicium v. treatment. Moreover, Illicium v.
reduced expression of adhesion molecules. It has been
reported that atherosclerotic lesion development is ac-
companied by upregulation of adhesion molecule levels.
In hyperlipidemic aortas, inflammation is associated with
atherosclerotic plaques in general [19, 21]. Therefore, Illi-
cium v. may be a potentially beneficial therapeutic drug
that targets the inflammatory cascade critical for patho-
genesis of hyperlipidemia-atherosclerosis.
In summary, we have demonstrated in HFD-fed ApoE−/−
mice that Illicium v. suppresses aortic atherosclerotic
lesion formation by antagonizing changes in body
weight, lipid levels, levels of blood pressure, inflamma-
tory cytokines, and adhesion molecules that are medi-
ated through iNOS activation. Beneficial effects of
Illicium v. may be explained by a significant reduction
in the inflammatory response. Therefore, Illicium v. is
a promising novel therapeutic drug for hyperlipidemia-
atherosclerosis treatment.
Conclusions
We have described an Illicium v.-mediated attenuation
of atherosclerotic lesion area (size of plaques) and
iNOS activation. In addition, we found an inhibition of
inflammatory cytokine and adhesion molecule expres-
sion, and subsequent blockade of the inflammatory re-
sponse by the plant extract. These results indicate that
Illicium v. may be a useful tool for developing new
therapeutic opportunities for treatment of hyperlipidemia-
atherosclerosis.
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